Company Overview and News

 
Podcast | Sensex rallies over 300 points; Nifty scales above 10,500

2018-05-25 moneycontrol
A strong day for Indian markets supported by short coverings as the S&P BSE Sensex rallied over 300 points and the Nifty50 managed to close above 50-days moving average and 100-DEMA on Thursday.

 
Jaypee Infra’s 700-acre land to remain with banks for now

2018-05-25 freepressjournal.in
New Delhi : The National Company Law Appellate Tribunal on Thursday admitted an appeal moved by ICICI Bank, Axis Bank and others challenging an order passed by the Allahabad bench of the National Company Law Tribunal directing Jaiprakash Associates to return over 700 acres of land to its subsidiary Jaypee Infratech.

 
Sensex builds on gains, up 187 points in early trade  

2018-05-25 freepressjournal.in
Mumbai: The BSE Sensex rose over 187 points in early trade today, extending yesterday’s rally on robust buying in IT, energy and banking stocks amid unabated purchases by domestic institutional investors. Asian shares were mixed after US President Donald Trump cancelled a planned meeting with North Korean leader Kim Jong Un.

 
Closing Bell: Sensex up over 300 pts, midcaps underperform; IT zooms, ONGC dips

2018-05-25 moneycontrol
Benchmark indices rose, driven by IT stocks, such as, Infosys and TCS on the back of a weak rupee. The IT index has gained 18 percent so far this year. The rupee has weakened by more than 7 percent so far this year, as surging crude oil prices weigh on India, the world’s third-largest importer, raising fears that soaring costs could drive up inflation and widen the trade deficit.

 
NCLAT admits lenders’ plea over surrender of Jaypee land

2018-05-25 livemint
New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Thursday admitted an appeal moved by ICICI Bank Ltd and other lenders challenging an order passed by National Company Law Tribunal’s (NCLT) Allahabad bench directing Jaiprakash Associates Ltd (JAL) to return 759 acres of land to its unit Jaypee Infratech Ltd (JIL).

 
Banks, IT stocks lift Sensex 318 pts; Nifty above 10,500, midcaps underperform

2018-05-25 moneycontrol
The market managed to recover all its previous session's losses on Thursday, led by short covering in beaten down stocks. Dovish Federal Reserve minutes, correction in crude oil prices and the recovery in rupee also aided sentiment.

 
Podcast | Sensex snaps 5-day losing streak; Nifty closes below 100-DMA

2018-05-22 moneycontrol
The S&P BSE Sensex snapped its 5-day losing streak and closed in positive making a small bullish candle on the daily candlestick charts on Tuesday. The Nifty50 also held on to its crucial support level placed at 10,500 levels, but closed below its 100-days moving average placed around 10,540.

 
HC asks Axis Bank to renew RCom bank guarantees

2018-05-21 livemint
New Delhi:The Delhi high court on Monday directed Axis Bank to renew all pending bank guarantees with respect to Reliance Communications Ltd (RCom), whether expired or yet to expire, as an interim measure.

 
Market Live: Sensex falls 200 pts, Midcap underperforms; Avenue Supermarts dips further

2018-05-21 moneycontrol
Buzzing: Shares of Dilip Buildcon fell 5.6 percent intraday as company's promoters pledged their shares with RBL Bank.

 
Market Live: Nifty struggles below 10,600, Midcap index extends losses; PSU banks gain

2018-05-21 moneycontrol
Buzzing: Shares of Indoco Remedies rose over 4 percent as USFDA has successfully completed the inspection at its manufacturing facilities.

 
Market Live: Sensex rebounds, Nifty above 10,600; Amara Raja, Century Textiles plunge

2018-05-21 moneycontrol
Pre-Opening Rate: Indostar Capital Finance share price settled at Rs 600 on the National Stock Exchange, up 4.9 percent compared to issue price of Rs 572.

 
Axis Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Financials, higher crude pull Sensex down 301 pts, Nifty below 10,600; Bajaj Finance up 4%

2018-05-18 moneycontrol
Benchmark indices extended losses for fourth consecutive session on Thursday, weighed by banking & financials, metals, infra and oil stocks.

 
After heavy losses, banks focus on being capital-light, reorient business models to push growth

2018-05-18 moneycontrol
The rise in bad loans and subdued corporate demand is driving banks to explore new business models, cross-sell products with more retail-oriented segments for growth. They are stepping up credit monitoring standards to lend to good quality customers.

 
Market Live: Sensex, Nifty Bank slip over 100 pts; HUL pips ITC in market cap

2018-05-18 moneycontrol
Fund Raising: Infrastructure firm NCC said its board will meet next week to consider raising funds through issuance of equity shares or warrants to promoters on preferential basis.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...